Boehringer takes alteplase to phase 3 for COVID, but drops antibodyBoehringer Ingelheim’s latecomer antibody therapy for COVID-19 has been side-lined, as the company focuses its attention on its Share XBoehringer takes alteplase to phase 3 for COVID, but drops antibodyhttps://pharmaphorum.com/news/boehringer-takes-alteplase-to-phase-3-for-covid-but-drops-antibody/
BMS re-joins Alzheimer’s push, paying $80m for Prothena’s tau antibodyJust a few days after Biogen abandoned its tau-targeting Alzheimer’s disease candidate gosuranemab, Bristol-Myers Squibb has opted into Share XBMS re-joins Alzheimer’s push, paying $80m for Prothena’s tau antibodyhttps://pharmaphorum.com/news/bms-re-joins-alzheimers-push-paying-80m-for-prothenas-tau-antibody/
Pair of R&D updates bolster GSK ahead of investor meetingGlaxoSmithKline (GSK) has reported encouraging data for its COVID-19 antibody sotrovimab, and an alliance with Halozyme to develop Share XPair of R&D updates bolster GSK ahead of investor meetinghttps://pharmaphorum.com/news/pair-of-rd-updates-bolster-gsk-ahead-of-investor-meeting/
Biogen abandons tau antibody for Alzheimer’s after phase 2 missBiogen has four other Alzheimer’s candidates in its clinical pipeline behind recently-approved Aduhelm, but one of them – Share XBiogen abandons tau antibody for Alzheimer’s after phase 2 misshttps://pharmaphorum.com/news/biogen-abandons-tau-antibody-for-alzheimers-after-phase-2-miss/
Regeneron drug saves lives in severe COVID-19, but it’s not for allPeople who cannot generate an effective immune response against COVID-19 can be protected with an infusion of Regeneron’s Share XRegeneron drug saves lives in severe COVID-19, but it’s not for allhttps://pharmaphorum.com/news/regeneron-drug-saves-lives-in-severe-covid-19-but-its-not-for-all/
AZ’s COVID jab tackles delta variant, but antibody fails clinical trialThe delta variant of COVID-19 may be holding back the lifting of lockdown restrictions in the UK, but Share XAZ’s COVID jab tackles delta variant, but antibody fails clinical trialhttps://pharmaphorum.com/news/azs-covid-jab-tackles-delta-variant-but-antibody-fails-clinical-trial/
GSK, Sanofi eye Q4 approval as COVID jab starts phase 3GlaxoSmithKline’s COVID-19 drive has advanced on two fronts, with the start of phase 3 trials of its Sanofi-partnered Share XGSK, Sanofi eye Q4 approval as COVID jab starts phase 3https://pharmaphorum.com/news/gsk-sanofi-eye-q4-approval-as-covid-jab-starts-phase-3/
EU starts rolling review of GSK’s antibody for COVID-19The EMA has begun a rolling review of a COVID-19 antibody developed by GlaxoSmithKline and Vir BioTech which Share XEU starts rolling review of GSK’s antibody for COVID-19https://pharmaphorum.com/news/eu-starts-rolling-review-of-gsks-antibody-for-covid-19/
EMA starts review of GSK/Vir COVID-19 antibodyThe EMA has started reviewing the emergency use application for GlaxoSmithKline and Vir Biotech’s COVID-19 antibody VIR-7831, which Share XEMA starts review of GSK/Vir COVID-19 antibodyhttps://pharmaphorum.com/news/ema-starts-review-of-gsk-vir-covid-19-antibody/
